110
Participants
Start Date
February 5, 2021
Primary Completion Date
November 2, 2021
Study Completion Date
December 13, 2021
efgartigimod PH20 SC
Subcutaneous injection with efgartigimod PH20 SC
efgartigimod IV
Intravenous infusion of efgartigimod
Investigator site 15 - HU0360013, Budapest
Investigator Site 7 - NL0310001, Leiden
Investigator Site 16 - HU0360020, Debrecen
Investigator site 5 - BE0320007, Ghent
Investigator Site 30 - DE490006, Berlin
Investigator Site 11 - US0010111, Amherst
Investigator Site 17 - IT0390003, Milan
Investigator Site 40 - US0010003, Chapel Hill
Investigator Site 38 - US0010077, Durham
Investigator Site 25 - ES0340002, Madrid
Investigator Site 47 - US0010113, Augusta
Investigator site 2 - US0010108, Boca Raton
Investigator site 1 - US0010110, Port Charlotte
Investigator site 4 - US0010008, Cordova
Investigator Site 27 - US0010006, Tampa
Investigator Site 43 - 0010019, Cleveland
Investigator Site 10 - ES0340039, Valencia
Investigator Site 29 - DE490009, Münster
Investigator Site 42 - US0010015, Kansas City
Investigator Site 46 - US0010009, Texas City
Investigator Site 28 - US0010066, Austin
Investigator site 2 - US0010032, Carlsbad
Investigator Site 41 - US0010004, Orange
Investigator Site 36 - RU0070014, Saint Petersburg
Investigator Site 35 - RU0070002, Novosibirsk
Investigator site 13 - GE9950002, Tbilisi
Investigator site 12 - GE9950001, Tbilisi
Investigator site 14 - GE9950003, Tbilisi
Investigator Site 44 - GE9950004, Tbilisi
Investigator Site 45 - GE9950016, Tbilisi
Investigator Site 39 - IT0390008, Roma
Investigator Site 31 - JP0810055, Sapporo
Investigator Site 18 - JP0810002, Chiba
Investigator site 6 - JPN0810004, Hanamaki
Investigator Site 33 - JP0810058, Hiroshima
Investigator Site 19 - JP0810007, Osaka
Investigator Site 34 - JP0810005, Sendai
Investigator Site 32 - JP0810059, Tokyo
Investigator Site 20 - JP0810009, Tokyo
Investigator Site 21 - PL0480001, Gdansk
Investigator Site 8 - PL0480007, Katowice
Investigator Site 9 - PL0480024, Krakow
Investigator Site 22 - PL0480005, Krakow
Investigator Site 23 - PL0480018, Lublin
Investigator Site 24 - PL0480022, Warsaw
Investigator Site 37 - ES0340021, Barcelona
Investigator Site 26 - ES0340038, Barcelona
Lead Sponsor
argenx
INDUSTRY